



Supplementary Materials:



**Figure S1.** Percentage of SARS-CoV-2 positive patients in various serological assays by post-PCR period for women (A), men (B), people over 65 years of age (C), people under 65 years of age (D), people hospitalized for COVID-19 (E), and people not requiring hospitalization (F).



**Figure S2.** Raw data of the results of the 208 samples by assay according to the collection period after the first positive PCR.

**Table S1.** Characteristics of the serological assays.

	ABBOTT®	BIORAD®	EUROIMMUN®	WANTAI®	INNOBI-OCHIPS®	NEUTRALIZ- ING ASSAY
<b>Targeted viral antigen</b>	Nucleocapsid	Nucleocapsid	Spike 1	Receptor-binding domain (RBD)	Spike1, Spike 2, Nucleocapsid, Receptor-binding domain and N-terminal domain	Spike
<b>Immunoglobulins detected</b>	IgG	Total antibodies	IgA and IgG	Total antibodies	IgG	Neutralizing antibodies
<b>Formats</b>	CLIA Indirect antigen down	ELISA Double antigen bridging	ELISA Indirect antigen down	ELISA Double antigen bridging	Multiplex ELISA	Pseudovirus assay
<b>Positivity threshold</b>	≥ 1.4	≥ 1	≥ 1.1	≥ 1	Algorithm according to arbitrary units for each antigen	Any titer > 10

CLIA : Chemiluminescence Immunoassay; ELISA : Enzyme-linked immunosorbent assay.